Cooper Companies’ (COO) Hold Rating Reiterated at Needham & Company LLC

Cooper Companies (NASDAQ:COO)‘s stock had its “hold” rating restated by equities research analysts at Needham & Company LLC in a report issued on Friday,Benzinga reports.

Several other analysts have also recently weighed in on COO. Citigroup reduced their price objective on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, December 6th. Wells Fargo & Company increased their price target on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Morgan Stanley cut their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Finally, StockNews.com lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $117.22.

Cooper Companies Trading Down 0.4 %

NASDAQ COO opened at $90.98 on Friday. The company has a market cap of $18.16 billion, a price-to-earnings ratio of 46.66, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. Cooper Companies has a twelve month low of $84.76 and a twelve month high of $112.38. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The business’s fifty day moving average is $92.56 and its 200 day moving average is $99.51.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. As a group, sell-side analysts expect that Cooper Companies will post 3.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Cooper Companies

Several hedge funds and other institutional investors have recently bought and sold shares of COO. Price T Rowe Associates Inc. MD grew its stake in shares of Cooper Companies by 517.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,529,477 shares of the medical device company’s stock valued at $324,466,000 after buying an additional 2,957,421 shares during the period. Norges Bank acquired a new stake in Cooper Companies in the fourth quarter valued at approximately $217,906,000. FMR LLC increased its holdings in shares of Cooper Companies by 97.6% during the fourth quarter. FMR LLC now owns 2,218,112 shares of the medical device company’s stock valued at $203,911,000 after acquiring an additional 1,095,805 shares in the last quarter. Victory Capital Management Inc. grew its position in Cooper Companies by 23.0% in the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock valued at $435,856,000 after purchasing an additional 737,726 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Cooper Companies during the fourth quarter worth $64,826,000. 24.39% of the stock is owned by institutional investors.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.